The Diabetes Trials Unit (DTU) is a fully registered UK Clinical Research Collaboration Clinical Trials Unit, specialising in performing local, national and multinational clinical trials related to the treatment and management of cardiometabolic and related disorders.
[More about the DTU]Patients and the public can get involved in research in a number of ways, including as a participant in a trial, by determining research priorities, or by contributing to the design or dissemination of research. Read more about getting involved here
Watch our video to hear the experience of previous trial participants and the views of our research staff.
Participants in our trials may be patients, with diabetes or other medical conditions, or healthy volunteers. Please visit our Trials page if you are interested getting involved to see our trials that are recruiting currently.
In a wide-ranging interview Professors Rury Holman and Amanda Adler discuss the origins of the UKPDS, review the trial findings, the discovery of the post-trial glycaemic and metformin legacy effects, and reveal some of the 44-year follow-up results.
[Watch interview]
The 44-year UK Prospective Diabetes Study (UKPDS) follow-up results were presented today at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden. The new data from the UKPDS, one of the longest ever studies of diabetes, show that the problems experienced by people with type 2 diabetes, including heart attacks, kidney failure and vision loss are not inevitable, with the benefits of early good blood glucose control persisting for decades....
[Read more...]
The EMpagliflozin in acute MYocardial Infarction (EMMY) trial was presented today by former DTU Research Fellows, Dr Harald Sourij and Dr Abderrahim Oulhaj, at the European Society of Cardiology (ESC) Congress in Barcelona with simultaneous publication in the European Heart Journal.
EMMY aimed to investigate whether empagliflozin treatment given in addition to guideline recommended post-MI therapy, and initiated within 72 hours after percutaneous coronary intervention in people with a large acute myocardial infarction, with or without diabetes, would result in a larger decline in NT-proBNP and a larger improvement in ejection fraction....
